Sacroiliac joint radiographic progression in axial spondyloarthritis is retarded by the therapeutic use of TNF inhibitors: 12-year data from the SCQM registry

Raphael Micheroli, Seraphina Kissling, Kristina Bürki, Pascale Exer, René Bräm, Michael J Nissen, Burkhard Möller, Michael Andor, Oliver Distler, Almut Scherer, Adrian Ciurea

ABSTRACT

Objectives To analyse the effect of tumour necrosis factor inhibitors (TNFi) on sacroiliac joint (SIJ) radiographic progression in axial spondyloarthritis (axSpA).

Methods Patients with axSpA in the Swiss Clinical Quality Management cohort with up to 12 years of follow-up and radiographic assessments every 2 years were included. SIJs were scored by two readers according to the modified New York criteria blinded to chronology. The relationship between TNFi use before or during a 2-year radiographic interval and SIJ progression was investigated using generalised estimating equation models with adjustment for potential confounding. Progression was defined as worsening of ≥1 grade in ≥1 SIJ and ignoring a change from 0 to 1 over 2 years, if both readers agreed. A third reading of radiographs was integrated in sensitivity analyses.

Results A total of 515 patients with axSpA contributed data to 894 radiographic intervals (24 progression events). In patients with complete covariate data, prior use of TNFi reduced the odds of progression (OR 0.21, 95% CI 0.07 to 0.65). A comparable effect was found for use of TNFi for ≥1 year within a 2-year radiographic interval (OR 0.21, 95% CI 0.08 to 0.55). The inhibitory impact of TNFi was confirmed if progression was demonstrated in 2/3 readings: OR 0.50, 95% CI 0.28 to 0.89 and OR 0.46, 95% CI 0.27 to 0.78 for TNFi treatment before and for ≥1 year within the interval, respectively.

Conclusion TNFi are associated with deceleration of SIJ radiographic progression in patients with axSpA if treatment is continued for ≥1 year.

INTRODUCTION

Axial spondyloarthritis (axSpA) is an inflammatory rheumatic disease that primarily affects the sacroiliac joints (SIJ) and the spine. There is increasing consensus that this disorder encompasses both non-radiographic and radiographic disease forms (nr-axSpA and r-axSpA, respectively), depending on whether clear sacroiliac damage is already observed on conventional X-rays. The latter is defined by the modified New York criteria (mNYc) for postinflammatory sacroiliac radiographic changes. While some patients with nr-axSpA may never develop definite SIJ structural lesions, a significant proportion of patients will evolve from nr-axSpA to r-axSpA, although the percentage over a period of 2–5 years seems rather small. Structural changes of the spine usually accumulate after substantial SIJ damage is established. Evidence is accruing that treatment with tumour necrosis factor inhibitors (TNFi) is able to decelerate the appearance of these spinal radiographic changes. Therefore, the question of whether TNFi might be able to retard radiographic progression at the level of the sacroiliac joints (SIJ) remains controversial.

WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT?

⇒ Observational studies suggest that treatment with tumour necrosis factor inhibitors (TNFi) can inhibit spinal radiographic progression in axial spondyloarthritis (axSpA).

⇒ Whether TNFi might be able to retard radiographic progression at the level of the sacroiliac joints (SIJ) remains controversial.

WHAT DOES THIS STUDY ADD?

⇒ TNFi are associated with retardation of SIJ radiographic progression in axSpA if treatment is continued for at least 1 year.

HOW MIGHT THIS IMPACT ON CLINICAL PRACTICE OR FURTHER DEVELOPMENTS?

⇒ Confirmation of a disease-modifying effect of TNFi at both sacroiliac and spinal levels strengthens the concept of axSpA being a single disorder with several phenotypes.

⇒ As structural damage in axSpA starts in the SIJ and continues in the spine, early and continued anti-inflammatory treatment might completely abrogate both sacroiliac and spinal progression.
changes. With regard to SIJs, treatment with TNFi for at least 12 months in a previous radiographic interval was associated with a lower SIJ progression in the following 2-year interval in a very recent observational study. Although the significance of SIJ structural changes has been questioned from a functional point of view, confirmation of an inhibition of radiographic progression not only at the level of the spine, but also of the SIJs, would strengthen the paradigm of axSpA being a single disorder. The aim of the study was to investigate the relationship between treatment with TNFi and SIJ radiographic progression independently of classification status as nr-axSpA and r-axSpA in a longitudinal analysis with 2-year clinical and radiographic intervals and up to 12 years of follow-up in a large observational cohort of patients with axSpA.

METHODS

Study population

The Swiss Clinical Quality Management (SCQM) Foundation in Rheumatic Diseases is associated with the Swiss Society for Rheumatology (SGR) and runs a national registry for inflammatory rheumatic diseases (rheumatoid arthritis, axSpA, psoriatic arthritis, undifferentiated arthritis, giant cell arteritis and polymyalgia rheumatica). The online database provides an integrated feedback system to patients and treating rheumatologists to be used as a quality management tool for treatment (treat-to-target decision making) during real-life clinical practice. All rheumatologists practising in Switzerland can be affiliated with SCQM, irrespective of them working in non-academic or academic institutions (rheumatology departments of 42 hospitals, including 5 university hospitals) or in private rheumatology practices. Approximately 50% of SCQM patients are followed in private practices. Treatment recommendations by the SGR stipulate that patients with inflammatory rheumatic diseases should be seen at least once a year by a rheumatologist. This is the basis for annual SCQM visits with comprehensive physician and patient questionnaires. Shorter questionnaires including disease activity measurements and clinical manifestations are recommended for intermediate visits and particularly before and 3 months after initiation of a new treatment. The data are available in an anonymised form for long-term observational studies. Patients provide informed consent at inclusion in the registry.

The ongoing axSpA cohort within SCQM was initiated in 2005. Inclusion criteria include a clinical diagnosis of axSpA (ankylosing spondylitis or other forms of SpA with predominantly axial disease) by a rheumatologist, irrespective of age, disease duration and treatment. The questionnaires for rheumatologists include all parameters relevant to assess spondyloarthritis and the fulfilment of the Assessment of SpondyloArthritis international Society classification criteria including prior MRI positivity, disease manifestations (presence of inflammatory back pain; presence of peripheral arthritis via a 44-joint homunculus, presence of enthesitis via a homunculus reflecting the Maastricht Ankylosing Spondylitis Enthesitis Score sites (modified to include the plantar fasciae), ever dactylitis), exact measurements for the Bath Ankylosing Spondylitis Mobility Index, exact start and stop dates for conventional and biological disease-modifying antirheumatic drugs, treatment with non-steroidal anti-inflammatory drugs (NSAIDs) and other analgesics as yes/no; levels of C-reactive protein (CRP), erythrocyte sedimentation rate and of haemoglobin; human leucocyte antigen B27 (HLA-B27) status; smoking status; information on physical activity (number of exercise units per week). There is no information on whether NSAIDs are used on demand or continuously between visits. The patient questionnaire includes the Patient Global Assessment, the Bath Ankylosing Spondylitis Disease Activity and Functional Indices (BASDAI and BASFI, respectively), assessment of quality of life (EuroQol 5 domains; EQ-5D) and the Short Form 36 (SF-36) questionnaire (later changed to the SF-12) on numerical rating scales. The online database automatically calculates the Ankylosing Spondylitis Disease Activity Score (ASDAS) and the patient-reported outcomes as soon as the rheumatologist and the patient fill in the respective data. The patient receives a reminder to fill in the questionnaires shortly ahead of the consultation, if the visit has been scheduled via the SCQM tool, allowing a treat-to-target treatment approach.

Given the gap in knowledge concerning radiographic progression and disease-modifying capacities of approved drugs, radiographic assessments were recommended from start of SCQM to be performed every 2 years (anterior-posterior pelvis radiograph, anterior and lateral radiograph of the lumbar spine, lateral radiograph of the cervical spine). The decision to perform radiographs remains with the rheumatologists and the patients. The radiographs are usually ordered in conjunction with an annual visit and are performed either immediately after the visit if the institution has a radiology department or an X-ray equipment or within days/weeks after the visit if the radiographs have to be performed elsewhere. Disease activity measurements were mapped to an X-ray date if available during a timeframe of ±30 days. A timeframe of 90 days before the X-ray and 30 days after the X-ray was considered for mapping other variables to a specific X-ray date. The visit closest to the X-ray was chosen if several measurements were available during the respective timeframe.

Inclusion criteria

Patients with a clinical diagnosis of axSpA in the SCQM Registry were included in the current study if they fulfilled the ASAS 2009 classification criteria and had at least 2 pelvis radiographs at an interval of 2 years±6 months, irrespective of classification status as nr-axSpA or r-axSpA. We used the central reading of pelvis radiographs in the SCQM database for classification purposes and selection of patients (‘database scoring’), as it was
available to rheumatologists for treatment decisions. This reading was provided by two members of the SCQM axSpA scientific board and a third independent adjudicator as soon as a radiograph was uploaded to the database as a service to the treating rheumatologist.

**Assessment of SIJ radiographic progression**

All pelvis radiographs of patients fulfilling the inclusion criteria of the current study were rescored by two trained and calibrated readers (AC and RM) independently. They were blinded to all other information. The readers scored all radiographs per patient without knowing their chronological order. The scoring was performed according to the mNYc: grade 0=normal; grade 1=suspicious changes; grade 2=minimal abnormalities; grade 3=unequivocal abnormalities; and grade 4=complete ankylosis.6 Informed by differences in the sensitivity to change of different definitions of radiographic progression at the level of the SIJ,8 21 the following primary outcome for progression was chosen: worsening of at least one grade in at least one SIJ and ignoring a change from 0 to 1 over 2 years. It was only considered to be present if both readers agreed. We used an alternative definition of radiographic SIJ progression as a secondary outcome: a change in the total mNY score (sacroilitis sum score (SSS)), expressed as a continuous variable from −8 to 8 (4 grades per SIJ with the outcome presented as the mean score of the 2 readers).7 8 The potential of improvement of the SIJ score during follow-up was also evaluated (reduction of at least one grade in at least one SIJ with a baseline score of at least 2 in the improved SIJ). We decided a priori to not assess progression from nr-axSpA to r-axSpA for the following reasons: first, the rate of progression from one disease state to the other within 2 years was shown to be rather slow, a fact that might severely impede demonstration of deceleration.7 8 Second, we have recently shown that the cut-off of SIJ scoring differentiating between nr-axSpA and r-axSpA seems suboptimal to predict clinically relevant outcomes.22 Finally, as already mentioned, sensitivity to change of progression between disease states is much lower than for the outcome chosen.8 21

Progression in the main analysis was only considered if both readers agreed on the outcome to only concentrate on undoubtful images in the context of the analysis of potential inhibition of progression. In a sensitivity analysis, the ‘database scoring’ of pelvis radiographs (see paragraph on inclusion criteria) was integrated in the analyses as a third reading. Progression according to the binary outcome as defined above was considered if it was observed in 2/3 readings. This analysis allowed for more adequate information on the extent of the measurement error (increase in background noise with more important worsening as well as improvement in SIJ scores).

**Statistical analyses**

Reliability of the scoring was assessed with weighted Kappa values of the right SIJ scores and the left SIJ scores of the two readers. All kappa values were interpreted according to Landis and Koch.23 In addition, we calculated the intraclass correlation coefficient (ICC; single unit, type agreement, two way) on the sum of the left and the right SIJ scores (SSS).

The relationship between TNFi treatment and radiographic progression over time was investigated using generalised estimating equations (GEE)24 in patients with a baseline SSS≤7 and available covariate information. The method takes into account the issue of repeated measurements within a patient. All GEE models were fitted using an exchangeable correlation structure. Binomial GEEs were used for the main models with binary outcomes, and Gaussian GEEs were used for the models that analyse the continuous change of the SSS within the radiographic interval. The GEE models were adjusted for potential confounders and/or explanatory variables for SIJ progression: baseline damage (baseline SSS), sex, symptom duration, HLA-B27 status, smoking status, NSAID use at start of each radiographic interval (yes/no) and disease activity at start of each radiographic interval as assessed by the ASDAS.20 ASDAS was replaced by BASDAI and CRP in a sensitivity analysis. Paralleling our analysis of the impact of TNFi on spinal radiographic progression,24 the following variables for TNFi use were introduced in the longitudinal models: (1) use of TNFi prior to the radiographic interval as yes/no if still ongoing, independently of the length of use and (2) treatment with TNFi during the 2-year radiographic interval as ≤1 year versus ≥1 year of continuous treatment versus no treatment. We checked for interaction between treatment with TNFi and treatment with NSAIDs. To address the potential issue of confounding by indication, a model was built up that was adjusted for the ASDAS value before start of TNFi. The ASDAS value at inclusion in SCQM was used in this model for patients not treated with TNFi.

**RESULTS**

A total of 515 patients with axSpA presented with at least 2 pelvis radiographs at an interval of 2 years±6 months (894 radiographic intervals). Baseline characteristics of these patients at first radiograph are provided in table 1 (male sex 66%, HLA-B27 positivity 80%, nr-axSpA 46.2%). In comparison with all patients with axSpA in SCQM (characteristics shown in the online supplemental table S1), patients with sequential radiographs were in a higher proportion in the nonradiographic disease state, were more often treated with TNFi and had lower disease activity measures (BASDAI, ASDAS, proportion of patients with enthesitis; table 1). Mean (IQR) time between radiographs was 2.1 (1.9; 2.3) years. The scores of both readers for each SIJ for the 1470 scored X-rays (at start and end of 894 intervals of 2 years±6 months) according to the mNY scoring system6 are provided in the online supplemental figure S1. Interobserver reliability assessed by the weighted Kappa was ‘moderate’ for both the right and left SIJ scores (0.49, CI 0.46 to 0.51 and 0.46, 0.49).
CI 0.44 to 0.49, respectively). The ICC of the agreement of the SSS yielded the same level of reliability: ‘moderate’ (ICC 0.64, CI 0.29 to 0.79). With regard to the binary SIJ outcome after 2 years (progression/regression), worsening of at least one grade in at least one SIJ and ignoring a change from 0 to 1 over 2 years, progression was observed in 24/703 radiographic intervals (3.4%, table 2). A 2-by-2 table for progression as observed by the two readers is shown in the online supplemental table S2. It was observed in 5/377 intervals with prior TNFi use (1.3%) and in 19/326 intervals without prior TNFi use (5.8%). Regression was observed in only 1/867 intervals (0.12%).

**Table 1** Baseline characteristics at first radiograph

| Parameter | All patients N=515 | Patients with the potential of SIJ progression (mean SSS≤7) N=415 | Patients with complete data in multivariable analyses N=302 |
|-----------|-------------------|-------------------------------------------------|-------------------------------------------------|
| Male sex, N (%) | 515 | 341 (66.2) | 415 | 258 (62.2) | 302 | 184 (60.9) |
| HLA-B27 positive, N (%) | 478 | 388 (81.2) | 387 | 308 (79.6) | 302 | 243 (80.5) |
| nr-axSpA, N (%) | 515 | 238 (46.2) | 415 | 238 (57.4) | 302 | 174 (57.6) |
| Age, years | 515 | 40.5 (10.9) | 415 | 39.6 (10.6) | 302 | 39.2 (10.6) |
| Symptom duration, years | 512 | 14.2 (10.6) | 414 | 12.4 (9.8) | 302 | 12.8 (9.5) |
| BASDAI | 439 | 4.1 (2.3) | 351 | 4.1 (2.2) | 302 | 4.1 (2.2) |
| ASDAS | 410 | 2.7 (1.1) | 328 | 2.7 (1.0) | 302 | 2.6 (1.0) |
| CRP, mg/L | 444 | 9.8 (14.8) | 358 | 8.7 (13.6) | 302 | 8.7 (14.0) |
| BASFI | 440 | 2.8 (2.4) | 353 | 2.6 (2.4) | 302 | 2.6 (2.3) |
| BASMI | 458 | 2.0 (2.0) | 370 | 1.5 (1.6) | 300 | 1.5 (1.5) |
| Current enthesitis, N (%) | 463 | 205 (44.3) | 374 | 172 (46.0) | 297 | 135 (45.5) |
| BMI 25–30, % | 465 | 151 (32.5) | 372 | 120 (32.3) | 283 | 90 (31.8) |
| BMI>30, % | 465 | 74 (15.9) | 372 | 61 (16.4) | 283 | 46 (16.2) |
| On NSAID treatment, N (%) | 463 | 364 (78.6) | 376 | 296 (78.7) | 302 | 235 (77.8) |
| On csDMARD treatment, N (%) | 515 | 62 (12.0) | 415 | 47 (11.3) | 302 | 31 (10.3) |
| On TNFi treatment, N (%) | 515 | 235 (45.6) | 415 | 181 (43.6) | 302 | 121 (40.1) |
| Years of TNFi treatment in treated patients | 235 | 2.6 (2.3) | 181 | 2.5 (2.2) | 121 | 2.8 (2.3) |
| Current smokers, N (%) | 466 | 169 (36.3) | 375 | 136 (36.3) | 302 | 110 (36.4) |
| Patients with different number of radiographic intervals*, N (%) | 515 | 415 | 302 |
| 1 interval | 288 (55.9) | 231 (55.7) | 182 (60.3) |
| 2 intervals | 126 (24.5) | 108 (26.0) | 75 (24.8) |
| 3 intervals | 63 (12.2) | 47 (11.3) | 31 (10.3) |
| 4 intervals | 28 (5.4) | 22 (5.3) | 12 (4.0) |
| 5 intervals | 7 (1.4) | 6 (1.4) | 2 (0.7) |
| 6 intervals | 3 (0.6) | 1 (0.2) | 0 (0.0) |

Except where indicated otherwise, values are the mean (SD).

ASDAS, Ankylosing Spondylitis Disease Activity Score; BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; BASFI, Bath Ankylosing Spondylitis Functional Index; BASMI, Bath Ankylosing Spondylitis Metrology Index; BMI, Body Mass Index; CRP, C-reactive protein (CRP) levels; csDMARD, conventional synthetic disease-modifying antirheumatic drug; HLA-B27, human leucocyte antigen B27; mSASSS, modified Stoke Ankylosing Spondylitis Spine Score; nr-axSpA, nonradiographic axial spondyloarthritis (central consensus scoring in database); NSAID, non-steroidal anti-inflammatory drug; SSS, Sacroiliitis Sum Score; TNFi, tumour necrosis factor inhibitor.

**SIJ radiographic progression over 2 years**

Patients with complete bilateral SIJ ankylosis as scored by at least one reader (SSS≥7, N=100) were excluded from further analyses. Baseline characteristics of the remaining patients (N=415) are depicted in table 1. Mean (±SD) change in the SSS was 0.1 (±0.4) points. A multivariable model was set up to identify factors associated with radiographic SIJ progression in patients with complete covariate data (N=302, baseline characteristics also shown in table 1). With progression defined as a change of at least 1 grade in at least one SIJ over 2 years and ignoring a change from 0 to 1, a total of 22 progression events were observed during overall 483 X-ray intervals in this
population. Progression from nr-axSpA to r-axSpA was observed in 16 intervals by reader 1 and in 11 intervals by reader 2 (only one interval with agreement). In patients with multiple 2-year intervals, 36/181 intervals were not consecutive. Prior TNFi use up to the X-ray interval was observed at start of 240/483 X-ray intervals (49.7%). The length of treatment was ≥4 years for 112 of these intervals. No prior TNFi treatment or already discontinued TNFi treatment was used as a reference in our model and observed at start of 243 X-ray intervals (203 intervals in TNFi-naive patients and 40 intervals in patients having discontinued TNFi, respectively). Use of TNFi up to the radiographic interval was associated with less progression in this model (OR 0.21, 95% CI 0.07 to 0.65; table 3). Baseline sacroiliac damage, male sex and disease duration were independently associated with more severe radiographic progression in this model (table 3). Sex differences in SIJ progression are also exemplified by the fact that only 4/22 progression events occurred in women, although 38.4% of radiographic intervals originated from women. None of the women demonstrating progression was treated with TNFi prior to the respective radiographic interval. Substituting BASDAI and CRP for ASDAS did not substantially affect the estimated effect of TNFi on progression (table 4). There was no significant interaction between treatment with TNFi and treatment with NSAIDs, suggesting no additional impact of concomitant treatment with NSAIDs (online supplemental table S3). We found a trend for an additive inhibitory effect for each additional year of TNFi treatment (OR 0.84, 95% CI 0.66 to 1.07, online supplemental table S4).

The impact of TNFi prior to the radiographic interval on progression was only slightly affected by adjusting for ASDAS before treatment start, performed to address the issue of confounding by indication (OR 0.15, 95% CI 0.04 to 0.56, table 5). The retardation of SIJ radiographic progression associated with the use of TNFi prior to the radiographic interval was confirmed when progression was defined as a change in the SSS over 2 years (−0.118 units, 95% CI −0.203 to −0.033; table 6). Current smoking was associated with a significantly higher change in SSS in this model (table 6).

| Table 2 | Rate of changes in the binary sacroiliac joint outcome measure |
|---------|---------------------------------------------------------------|
| **Outcome** | **X-ray intervals of 2 years ± 6 months** | **Intervals with potential progression** | **Intervals with potential regression** |
| | **894 intervals in 515 patients** | **N=703** | **N=867** |
| **Main analysis: 2 readers** | | | |
| Progression | 24 (3.4%) | | |
| Regression | 1 (0.12%) | | |
| **Sensitivity analysis: integrating a third scoring** | | | |
| Progression | 105 (14.9%) | | |
| Regression | 21 (2.4%) | | |

*Change considered on agreement of both primary readers.
†Change considered on agreement in 2/3 readings. Progression defined as worsening of at least one grade in at least one SIJ and ignoring a change from 0 to 1 over 2 years; regression defined as improvement of at least one grade in at least one SIJ and a baseline value of at least two in the improved joint.

| Table 3 | Multivariable analysis for identification of factors associated with radiographic SIJ progression defined as a change of at least one grade in at least one SIJ and ignoring a change from 0 to 1 over 2 years |
|---------|----------------------------------------------------------------------------------|
| **Variable** | **OR** | **95% CI** | **P value** |
| Prior TNFi use up to the start of X-ray interval yes/no | 0.21 | 0.07 to 0.65 | 0.006 |
| Baseline sacroiliac damage (0–7) at start of each X-ray interval | 1.35 | 1.02 to 1.77 | 0.04 |
| Female sex | 0.26 | 0.07 to 0.94 | 0.04 |
| Symptom duration | 1.06 | 1.01 to 1.10 | 0.01 |
| Current smoking | 2.47 | 0.75 to 8.11 | 0.14 |
| HLA-B27 negative | 0.88 | 0.18 to 4.35 | 0.87 |
| NSAID use at start of each X-ray interval | 0.86 | 0.25 to 2.98 | 0.81 |
| ASDAS at start of each X-ray interval | 1.06 | 0.62 to 1.81 | 0.82 |

Analysis in 302 patients and 483 X-ray intervals (22 events).
ASDAS, Ankylosing Spondylitis Disease Activity Score; HLA-B27, human leucocyte antigen B27; NSAID, non-steroidal anti-inflammatory drug; SIJ, sacroiliac joint; TNFi, tumour necrosis factor inhibitor.
We next investigated whether the use of TNFi during a 2-year radiographic interval had an impact on radiographic progression using the binary primary outcome. Out of a total 483 X-ray intervals, there was no TNFi use at all during 144 intervals, TNFi use for at least 1 year in 314 intervals, and TNFi use for <1 year in 25 intervals. Use of TNFi during the radiographic interval was associated with lower odds of progression, but the difference reached statistical significance only if biological treatment was used for more than 1 year (OR 0.21, 95% CI 0.08 to 0.55 vs OR 0.38, 95% CI 0.04 to 3.39 for TNFi use <1 year; table 7). Retardation of SIJ radiographic progression was also found with the use of TNFi during the X-ray interval when progression was defined as a change in the SSS over 2 years (online supplemental table S5).

Sensitivity analyses after integration of a third reading of radiographs

Finally, we analysed the primary outcome after integrating a third reading of the radiographs and considering a change in the binary SIJ outcome measure if it was observed in 2/3 readings. Measurement error of SIJ scoring was more clearly exemplified in this second approach by a higher progression as well as regression rate (table 2). Use of TNFi before the radiographic interval and for at least 1 year during the radiographic interval was associated with significant lower odds for radiographic progression (OR 0.50, 95% CI 0.28 to 0.89 and OR 0.46, 95% CI 0.27 to 0.78, respectively, in these adjusted longitudinal analyses, table 8).
described for the mNY grading system,\(^6\)\(^–\)\(^8\) we have chosen the one that proved to be the most sensitive to change:\(^8\)\(^–\)\(^21\): worsening of ≥1 grade in ≥1 SIJ and ignoring a change from 0 to 1 over 2 years. Moreover, progression between nr-axSpA and r-axSpA during a 2-year interval is low,\(^7\) and the existing cut-off differentiating them proved of limited benefit to predict important outcomes in a recent analysis of our cohort.\(^22\)

Recognition of structural damage according to the mNYc is subject to considerable inter-reader and intra-reader variation.\(^25\) In line with this observation, not only progression, but also regression in the SIJ score has been detected, most likely reflecting measurement error.\(^7\)\(^–\)\(^26\). This background ‘noise’ might be due or amplified by several factors: the quality of the films, the complex anatomy of the SIJs, bowel content overlapping/obscuring the view on SIJs, and the fact that the definition of the individual grades of the score is partly open to interpretation. To be able to estimate ‘true’ progression, worsening as well as improvement in the score has to be accounted for. In the context of the analysis of potential inhibition of progression, however, concentration on undoubtful images might be of some interest. We have therefore chosen a conservative approach with only two scorers blinded to the chronology of the images and defined progression if both readers agreed on the outcome. A different scoring approach with two readers knowing the sequence of images was chosen by Torgutalp et al in their analysis of the German Spondyloarthritids inception cohort (GESPIC).\(^11\) The fact that retardation of progression by TNFi was found independently of the scoring method adds to the validity of the results. Integration of a third reading in our analysis—with progression defined if the primary outcome was observed in 2/3 readings—allowed for more adequate information on the extent of the measurement error. While in both our analyses, use of TNFi was associated with a lower radiographic SIJ progression, the size of the estimate decreased with an increase in background noise.

Regardless of the approach used (two or three readings), there was at least a 50% decrease in the odds of progressing by at least one grade in one SIJ over 2 years, after excluding a change from grade 0 to grade 1, in patients treated with TNFi before a 2-year radiographic interval. Male sex was associated with a significantly higher rate of progression. While women contributed to almost 40% of radiographic intervals, only 4/22 progression events were found in female patients and none of them was treated with TNFi prior to the respective

| Variable | Estimate | 95% CI | P value |
|----------|----------|--------|---------|
| Prior TNFi use up to the start of X-ray interval yes/no | -0.118 | -0.203 to -0.033 | |
| Baseline sacroiliac damage (0–7) at start of each X-ray interval | -0.017 | -0.041 to 0.207 | |
| Female sex | -0.081 | -0.170 to 0.007 | |
| Symptom duration | 0.001 | -0.004 to 0.005 | |
| Current smoking | 0.087 | 0.001 to 0.173 | |
| HLA-B27 negative | 0.084 | -0.038 to 0.207 | |
| NSAID use at start of each X-ray interval | -0.018 | -0.112 to 0.077 | |
| ASDAS at start of each X-ray interval | 0.011 | -0.034 to 0.056 | |

Analysis in 302 patients and 483 X-ray intervals (22 events).

Table 7  Impact of TNFi use within a 2-year radiographic interval on sacroiliac joint radiographic progression defined as a change of at least one grade in at least one SIJ and ignoring a change from 0 to 1

| Variable | OR | 95% CI | P value |
|----------|----|-------|---------|
| TNFi use during X-ray interval ≥1 year (ref: no TNFi use during interval) | 0.21 | 0.08 to 0.55 | 0.001 |
| TNFi use during X-ray interval <1 year (ref: no TNFi use during interval) | 0.38 | 0.04 to 3.39 | 0.39 |
| Baseline sacroiliac damage at start of each X-ray interval (0–7) | 1.33 | 1.00 to 1.77 | 0.047 |
| Female sex | 0.27 | 0.07 to 1.00 | 0.05 |
| Symptom duration | 1.05 | 1.01 to 1.10 | 0.02 |
| Current smoking | 2.21 | 0.71 to 6.89 | 0.17 |
| HLA-B27 negative | 0.71 | 0.14 to 3.81 | 0.70 |
| NSAID use at start of each X-ray interval | 0.93 | 0.26 to 3.37 | 0.91 |
| ASDAS at start of each X-ray interval | 1.30 | 0.75 to 2.27 | 0.35 |

302 patients and 483 intervals (22 events).

ASDAS, Ankylosing Spondylitis Disease Activity Score; BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; CRP, C-reactive protein; HLA-B27, human leucocyte antigen B27; NSAID, non-steroidal anti-inflammatory drug; SIJ, sacroiliac joint; TNFi, tumour necrosis factor inhibitor.
radiographic interval. As a consequence, the study was underpowered to report a separate effect of treatment with TNFi on progression in women. There is a fundamental need for larger and longer studies to assess whether our findings can also be confirmed in a female population.

Interestingly, use of TNFi for at least 1 year during the 2-year X-ray interval was associated with a comparably lower SIJ radiographic progression. This is in contrast to the analysis performed in the GESPIC cohort, in which only treatment in the previous radiographic interval, but not in the current interval was associated with deceleration of progression. The outcome of progression chosen here, however, could not be analysed thoroughly in GESPIC, as there was no progression according to this semiquantitative system cannot be regarded as being equidistant. The difference in progression of −0.12 units of the SSS between TNFi-treated and untreated patients is, therefore, more difficult to interpret. A very comparable estimate of −0.09 units has been demonstrated in the German cohort for patients treated for at least 12 months with TNFi in the previous interval in comparison to untreated patients. To put this into perspective, our findings can also be compared with a recent study of SIJ radiographic progression in patients treated with etanercept over 6 years: a mean change of +0.20 units was detected during the first 2 years, followed by a change of −0.22 units between year 2 and 4 and −0.09 units between year 4 and 6.

It has been argued that SIJ radiographic progression is of limited functional relevance, as an increase in one radiographic sacroiliitis grade in one joint was only associated with a functional deterioration of 0.1 BASFI points. The significance of spinal structural damage on impairments in physical function are, in contrast, beyond controversy. Formation of spinal syndesmophytes in axSpA can occur in the absence of definite sacroiliac changes in a limited proportion of patients and could affect function and mobility. We could not assess this issue here, as spinal radiographs were not available in all patients. While 8 out of 88 patients with nr-axSpA had at least one syndesmophyte in our previous analysis of spinal radiographic progression in our cohort, only one patient had a modified Stoke Ankylosing Spondylitis Spinal Score (range 0–72) >10. Axial inflammation is expected, therefore, to have a much higher impact on function and mobility in nr-axSpA than the very limited structural damage documented. As more severe SIJ postinflammatory changes are associated with much higher baseline spinal osteoproliferative changes as well as with spinal radiographic progression, deceleration of SIJ structural damage might imply in the context of a

---

### Table 8  
Sensitivity analysis: integrating a third reading of radiographs for the multivariable analysis for identification of factors associated with radiographic SIJ progression defined as a change of at least one grade in at least one SIJ and ignoring a change from 0 to 1

| Variable                              | A. TNFi use before the 2-year radiographic interval | B. TNFi use during the 2-year radiographic interval |
|---------------------------------------|----------------------------------------------------|----------------------------------------------------|
|                                       | OR        | 95% CI       | P value  | OR        | 95% CI       | P value  |
| Prior TNFi use up to the start of X-ray interval yes/no | 0.50     | 0.28 to 0.89 | 0.02     | 0.46     | 0.27 to 0.78 | <0.01   |
| TNFi use during X-ray interval ≥1 year | 1.12     | 0.97 to 1.29 | 0.12     | 1.11     | 0.97 to 1.28 | 0.13     |
| TNFi use during X-ray interval <1 year | 0.74     | 0.44 to 1.26 | 0.27     | 0.73     | 0.43 to 1.26 | 0.26     |
| Baseline sacroiliac damage at start of each X-ray interval (0–7) | 1.00     | 0.97 to 1.03 | 0.99     | 1.00     | 0.97 to 1.03 | 0.93     |
| Female sex                           | 1.29     | 0.76 to 2.18 | 0.35     | 1.23     | 0.73 to 2.08 | 0.43     |
| Symptom duration                     | 1.99     | 1.04 to 3.80 | 0.04     | 1.91     | 1.00 to 3.66 | 0.05     |
| Current smoking                      | 0.72     | 0.40 to 1.29 | 0.27     | 0.71     | 0.40 to 1.28 | 0.26     |
| HLA-B27 negative                     | 0.85     | 0.64 to 1.14 | 0.28     | 0.95     | 0.72 to 1.25 | 0.69     |
| NSAID use at start of each X-ray interval | 0.72     | 0.40 to 1.29 | 0.27     | 0.71     | 0.40 to 1.28 | 0.26     |
| ASDAS at start of each X-ray interval | 0.85     | 0.64 to 1.14 | 0.28     | 0.95     | 0.72 to 1.25 | 0.69     |

Three hundred one patients with 477 intervals (87 events). 
ASDAS, Ankylosing Spondylitis Disease Activity Score; BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; CRP, C-reactive protein; HLA-B27, human leucocyte antigen B27; NSAID, non-steroidal anti-inflammatory drug; SIJ, sacroiliac joint; TNFi, tumour necrosis factor inhibitor.
continued treatment with TNFi a further retardation of spinal progression and the expected later impairments in function, mobility and health-related quality of life.30

The lack of MRI data paralleling X-ray data represents the major limitation of our analysis, but is inherent to the observational data of this cohort, gathered in>50% of patients from private rheumatology practices.28 We do not have information on the proportion and the characteristics of patients not participating in SCQM. Moreover, the need for at least two radiographic assessments to analyse progression biased the study population towards a slightly less severe disease phenotype. We can only speculate on the reasons of these differences. The presence of sequential radiographs might indicate a more compliant patient population with regular consultations with the rheumatologist, more frequent approval of non-pharmacological and pharmacological treatment recommendations and, therefore, lower disease activity. At least with regard to the population with complete covariate data, baseline characteristics were comparable to the whole population in which SIJ radiographic progression could be assessed.

In conclusion, our data suggest that treatment with TNFi in axSpA has a significant inhibitory effect on SIJ radiographic progression if treatment is continued for at least 1 year.

Author affiliations
1 Department of Rheumatology, University of Zurich, Zurich, Switzerland
DataScience, SCQM Foundation, Zurich, Switzerland
3 Praxis Rheuma-Basel, Basel, Switzerland
Swiss Ankylosing Spondylitis Association, Zurich, Switzerland
5 Department of Rheumatology, Hopitaux Universitaires de Geneve Hospital de Beau-Sejour, Geneva, Switzerland
Department of Rheumatology, Clinical Immunology and Allergy, University Hospital of Bern, Bern, Switzerland
Private Rheumatology Practice, Uster, Switzerland

Twitter Raphael Micheroli @ramicheroli

Acknowledgements We thank all patients and their rheumatologists for participation and the whole SCQM staff for data management. A list of contributing rheumatology private practices and hospitals can be found at www.scqm.ch/institutions.

Contributors Study conception and design: AC, AS, SK and RM. Acquisition of data: AC, BM, KB, MA, MJN, PE, OD, RB, RM. Statistical analysis: SK and AS. All authors contributed to the interpretation of data. AC wrote the manuscript and all authors revised the manuscript and approved the final manuscript to be published. AC accepts full responsibility for the finished work, had access to the data, and controlled the decision to publish.

Funding The SCQM foundation is supported by the Swiss Society of Rheumatology and by Abbvie, Biogen, iQone, Janssen, Lilly, Merck Sharp & Dohme, Novartis, Pfizer, Samsung Bioepis, Sandoz. This study was supported by a grant from the Stiftung für Rheumaforschung to SCQM. The study sponsor had no role in the study design or in the collection, analysis or interpretation of the data, the writing of the manuscript or the decision to submit the manuscript for publication. Publication of this article was not contingent upon approval by the study sponsor.

Competing interests AC received honoraria for lectures or presentations from Abbvie, Merck Sharpe & Dohme, Novartis, Pfizer, Samsung Bioepis, Sandoz. AS received consulting fees from Pfizer and support for attending meetings from Gilead. BM received speaking fees from Janssen, Novartis and Pfizer and support for attending meetings from Janssen and Pfizer. MJN received consulting and/or speaking fees from Abbvie, Eli Lilly, Janssen, Novartis and Pfizer and a research grant from Novartis. OD received consulting fees from Abbvie. PE received financial support from UCB for attending a meeting. RM received honoraria for lectures or presentations from Abbvie, Eli Lilly, Janssen, Gilead and Pfizer. KB, MA, RB, and SK declare they have no conflicts of interest.

Patient consent for publication Consent obtained directly from patient(s)

Ethics approval This study involves human participants and was approved by Ethics Committee of the Canton of Zurich (KEK-ZH-Nr. 2014-0439). Participants gave informed consent to participate in the study before taking part.

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement All data relevant to the study are included in the article or uploaded as supplementary information.

Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

ORCID iDs Raphael Micheroli http://orcid.org/0000-0002-8918-7304 Michael J Nissen http://orcid.org/0000-0002-6326-1764 Oliver Distler http://orcid.org/0000-0002-0546-8310 Adrian Ciurea http://orcid.org/0000-0002-7870-7132

REFERENCES
1 Sieper J, Podubranny D. Axial spondyloarthritis. Lancet 2017;390:73–84.
2 Taurog JD, Chhabra A, Colbert RA. Ankylosing spondylitis and axial spondyloarthritis. N Engl J Med 2016;374:2563–74.
3 Rudwaleit M, van der Heijde D, Landewe R, et al. The development of assessment of spondyloarthritis International Society classification criteria for axial spondyloarthritis (Part I): validation and final selection. Ann Rheum Dis 2009;68:777–83.
4 Robinson PC, van der Linden S, Khan MA, et al. Axial spondyloarthritis: concept, construct, classification and implications for therapy. Nat Rev Rheumatol 2021;17:109–18.
5 Boel A, Moito A, van der Heijde D, et al. Do patients with axial spondyloarthritis with radiographic sacroiliitis fulfill both the modified New York criteria and the ASAS axial spondyloarthritis criteria? Results from eight cohorts. Ann Rheum Dis 2019;78:1545–9.
6 van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum 1984;27:361–8.
7 Podubranny D, Rudwaleit M, Haibl E, et al. Rates and predictors of sacroiliac radiographic progression over 2 years in patients with spinal spondyloarthritis. Ann Rheum Dis 2011;70:1369–73.
8 Dougados M, Sepriano A, et al. Sacroiliac radiographic progression in recent onset axial spondyloarthritis: the 5-year data of the DESIR cohort. Ann Rheum Dis 2017;76:1823–8.
9 Hebeisen M, Micheroli R, Scherer A, et al. Spinal radiographic progression in axial spondyloarthritis and the impact of classification as nonradiographic versus radiographic disease: data from the Swiss clinical quality management cohort. PLoS One 2020;15:e0230268.
10 Baraliakos X, Gensler LS, D’Angelo S, et al. Biologic therapy and spinal radiographic progression in patients with axial spondyloarthritis: a structured literature review. Ther Adv Musculoskelet Dis 2020;12:1759720X2090604–17.
11 Torgutalp M, Rios Rodriguez V, Proft F, et al. Treatment with tumor necrosis factor inhibitors is associated with a time-shifted retardation of radiographic sacroiliitis progression in patients with axial spondyloarthritis: 10-year results from the German spondyloarthritis inception cohort. Arthritis Rheumatol 2022;74:1515–23.
12 Braun J, Kiltz U, Baraliakos X. Significance of structural changes in the sacroiliac joints of patients with axial spondyloarthritis detected by MRI related to patients symptoms and functioning. Ann Rheum Dis 2022;81:11–14.

Micheroli R, et al. RMD Open 2022;8:e002551. doi:10.1136/rmdopen-2022-002551
13 Baeten D, Breban M, Lories R, et al. Are spondylarthritides related but distinct conditions or a single disease with a heterogeneous phenotype? *Arthritis Rheum* 2013;65:12–20.

14 Ciurea A, Scherer A, Exer P, et al. Tumor necrosis factor α inhibition in radiographic and nonradiographic axial spondyloarthritis: results from a large observational cohort. *Arthritis Rheum* 2013;65:3096–106.

15 Sieper J, Rudwaleit M, Baraliakos X, et al. The assessment of spondyloarthritides International Society (ASAS) Handbook: a guide to assess spondyloarthritis. *Ann Rheum Dis* 2009;68 Suppl 2:s1–44.

16 Heuft-Dorenbosch L, Spoorenberg A, van Tubergen A, et al. Assessment of enthesitis in ankylosing spondylitis. *Ann Rheum Dis* 2003;62:127–32.

17 van der Heijde D, Landewé R, Fedtkeller E. Proposal of a linear definition of the Bath ankylosing spondylitis Metrology index (BASMI) and comparison with the 2-step and 10-step definitions. *Ann Rheum Dis* 2008;67:489–93.

18 Garrett S, Jenkinson T, Kennedy LG, et al. A new approach to defining disease status in ankylosing spondylitis: the Bath ankylosing spondylitis disease activity index. *J Rheumatol* 1994;21:2286–91.

19 Calin A, Jones SD, Garrett SL, et al. Bath ankylosing spondylitis functional index. *Br J Rheumatol* 1995;34:793–4.

20 Lukas C, Landewé R, Sieper J, et al. Development of an ASAS-endorsed disease activity score (ASDAS) in patients with ankylosing spondylitis. *Ann Rheum Dis* 2009;68:18–24.

21 Sepriano A, Rudwaleit M, Sieper J, et al. Five-year follow-up of radiographic sacroiliitis: progression as well as improvement? *Ann Rheum Dis* 2016;75:1262–3.

22 Ciurea A, Weber U, Stekhoven D, et al. Treatment with tumor necrosis factor inhibitors in axial spondyloarthritis: comparison between private rheumatology practices and academic centers in a large observational cohort. *J Rheumatol* 2015;42:101–5.